Exelixis Inc

Type: Company
Name: Exelixis Inc
Nationality: United States
Web Address: http://www.exelixis.com/
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma

LONDON, October 20, 2014 /PRNewswire/ --Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ... [Published PR Newswire: Financial Services - Oct 20 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 2 reports

Exelixis, Inc. To Vacate Most Of Its South San Francisco Office Space

A biotech firm that laid off two-thirds of its workforce last month is reportedly vacating most of its South San Francisco office space.Exelixis executives plan to sublease almost 200,000 square feet of their 215,000-square-foot complex on Grand Avenue, ... [Published BioSpace - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

NASDAQ:EXEL Investor Alert: Investigation over possible Securities Laws Violations by Exelixis, Inc.

The Shareholders Foundation announces that an investigation on behalf of investors of Exelixis , Inc. (NASDAQ:EXEL) shares was initiated over potential securities laws violations by Exelixis and certain of its directors and officers in connection certain ... [Published Empowered News - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis ... [Published Business Wire Health News - Oct 14 2014]
Entities: Exelixis Inc, NASDAQ
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Is Exelixis, Inc. Stock a Bad News Buy?

Clinical or regulatory setbacks can cause biotechnology stocks to crash in a hurry. On occasion, the market's pessimism isn't entirely warranted, setting the stock up for an equally impressive comeback. Deciphering which "bad news biotechs" are bargains ... [Published Motley Fool Discussion Boards - Oct 13 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Exelixis Short Interest Up 10.4% in September (EXEL)

Shares of Exelixis (NASDAQ:EXEL) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 52,981,362 shares, a growth of 10.4% from the September 15th total of 48,000,678 shares, ... [Published American Banking News - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Exelixis Receives Average Rating of “Hold” from Analysts (NASDAQ:EXEL)

Shares of Exelixis (NASDAQ:EXEL) have received an average recommendation of "Hold" from the seven ratings firms that are presently covering the company, . Three analysts have rated the stock with a hold recommendation and one has issued a buy recommendation ... [Published American Banking News - Oct 07 2014]
Entities: Exelixis Inc, NASDAQ, Rating
First reported Sep 29 2014 - Updated Sep 30 2014 - 2 reports

Morning Buzz: Exelixis, Inc. (EXEL), Alimera Sciences Inc (ALIM), Dreamworks Animation (DWA)

Shares of Exelixis, Inc. (EXEL) are up almost 23% to $1.91 in pre-market trading Monday after the company announced positive results from coBRIM, the phase 3 pivotal trial of cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination ... [Published Wall Street Pit - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 3 reports

Genentech, Exelixis drug combo slows deadly skin cancer

Exelixis Inc. stock surged before backing off Monday after partner Genentech Inc. said a late-stage study that combined Exelixis' cobimetinib and Genentech's Zelboraf indicated that advanced skin cancer patients could live more than three months long ... [Published San Francisco Business Times - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 2 reports

Roche, GSK melanoma pill combinations look similar in showdown

* Roche set to compete with established GSK combination * Different side effects may determine choice of regimen * Shares (Berlin: DI6.BE - news) in Roche's biotech partner Exelixis (NasdaqGS: EXEL - news) jump 20 pct (Adds Exelixis share price jump, ... [Published Yahoo! Finance UK and Ireland - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Why Exelixis, Inc. Stock Is Soaring Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.What: Shares of small-cap biopharma Exelixis (NASDAQ: EXEL Per the press ... [Published Motley Fool - Sep 29 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Shares of Exelixis Fall Below Previous 5...

Exelixis (NASDAQ:EXEL) traded at a new 52-week low today of $1.55. Approximately 4.9 million shares have changed hands today, as compared to an average 30-day volume of 4.9 million shares.Exelixis, Inc. is involved in comparative genomics and model system ... [Published Financial News Network online - Sep 23 2014]

Quotes

"LGS is a difficult disease to treat and can have devastating effects on families. At Eisai, we seek to make further contributions to help address the diversified needs of epilepsy patients and their families as part of our corporate human healthhealth care (hhc) mission" said Lynn Kramer, chief clinical officer, president, neuroscience and general medicine, PCU Eisai Product Creation Systems, at Eisai Inc
Original Article: NEXT ARTICLE More From BioPortfolio on "Exelixis soars after drugmaker details results from study of potential skin cancer treatment"
...to the European Medicines Agency and plans to file a New Drug Application NDA) to the FDA later this year in the U S Exelixis management stated: "our partner Genentech sponsored a rigorous and well-run trial, and the results, including a significant increase in progression free survival and a high objective response rate, are compelling" . This news has me feeling bullish on shares in the near-term, but the stock has a long way to go just to be back to even where I recommended it just...
...Alise Reicin, vice president, oncology, Merck Research Laboratories. "We are encouraged by the signals of anti-tumour activity in advanced gastric cancer, and are eager to move ahead with the Phase 2 study to better understand the potential of pembrolizumab in advanced gastric cancer."

More Content

All (114) | News (75) | Reports (0) | Blogs (34) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Analyst Scanner on Biotech Equities - Amgen, Ex... [Published PR Newswire: Financial Services - Oct 20 2014]
West Coast Biotech Roundup: Illumina, Atara, In... [Published BioPortfolio - Oct 17 2014]
Exelixis, Inc. To Vacate Most Of Its South San ... [Published BioSpace - Oct 16 2014]
Biotech firm to vacate most of its South San Fr... [Published San Francisco Business Times - Oct 16 2014]
FDA grants priority reviews for Eisai's for ruf... [Published Pharma Letter - Oct 15 2014]
NASDAQ:EXEL Investor Alert: Investigation over ... [Published Empowered News - Oct 15 2014]
Exelixis to Release Third Quarter 2014 Financia... [Published Business Wire Health News - Oct 14 2014]
Is Exelixis, Inc. Stock a Bad News Buy? [Published Motley Fool Discussion Boards - Oct 13 2014]
Exelixis Short Interest Up 10.4% in September (... [Published American Banking News - Oct 10 2014]
West Coast Biotech Roundup: CareFusion, Sunesis... [Published BioPortfolio - Oct 09 2014]
Exelixis Receives Average Rating of “Hold” from... [Published American Banking News - Oct 07 2014]
GET YOUNG SCIENTISTS INVOLVED IN THE BUSINESS E... [Published U-T San Diego - Oct 06 2014]
Roche Presents Data on Cancer Immunotherapy Can... [Published Zacks.com - Oct 03 2014]
Exelixis: The Losing Streak Continues (EXEL) [Published Individual.com - Oct 01 2014]
Genentech gets good news on breast cancer drug,... [Published San Francisco Chronicle - Sep 30 2014]
Genentech gets good news on breast cancer drug,... [Published Tech Chronicles - Sep 30 2014]
Former Exelixis VP Joins as Technology Transact... [Published Latham & Watkins - Sep 29 2014]
Genentech, Exelixis drug combo slows deadly ski... [Published San Francisco Business Times - Sep 29 2014]
Melanoma drug trials bring good news to beleagu... [Published Tech Chronicles - Sep 29 2014]
Cancer drug stocks on the move amid striking data [Published NBR.com - Sep 29 2014]
Exelixis soars after drugmaker details results ... [Published BioPortfolio - Sep 29 2014]
Why Exelixis, Inc. Stock Is Soaring Today [Published Motley Fool - Sep 29 2014]
BUZZ-U.S. Stocks on the Move-Ambit, Athlon, Ton... [Published Reuters - Sep 29 2014]
Update: Exelixis Announces Very Positive Result... [Published Seeking Alpha - Sep 29 2014]
Morning Market Movers [Published Benzinga.com - Sep 29 2014]
ESMO: Bristol-Myers, Roche, AstraZeneca, GSK, M... [Published FierceBiotech - Sep 29 2014]
Roche, GSK melanoma pill combinations look simi... [Published Yahoo! Finance UK and Ireland - Sep 29 2014]
UPDATE 1-Roche, GSK melanoma pill combinations ... [Published CNBC - Sep 29 2014]
Morning Buzz: Exelixis, Inc. (EXEL), Alimera Sc... [Published Wall Street Pit - Sep 29 2014]
Morning Buzz: Exelixis, Inc. (EXEL), Alimera Sc... [Published Atlanta Journal And Constitution - Sep 29 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Analyst Scanner on Biotech Equities - Amgen, Ex... [Published PR Newswire: Financial Services - Oct 20 2014]
LONDON, October 20, 2014 /PRNewswire/ --Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ...
Exelixis to Release Third Quarter 2014 Financia... [Published Business Wire Health News - Oct 14 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis ...
Genentech gets good news on breast cancer drug,... [Published Tech Chronicles - Sep 30 2014]
Genentech has had an eventful last few days. Its melanoma drug with Exelixis delivered positive results in a late-stage trial, as we previously reported. More very good news for the South San Francisco biotech: a regimen involving its breast cancer drug ...
Melanoma drug trials bring good news to beleagu... [Published Tech Chronicles - Sep 29 2014]
Exelixis has been on a roller coaster lately. Earlier this month, the South San Francisco biotech company’s stock plummeted after it announced that its prostate cancer drug had flopped in trials and that 70 percent of its workforce would be laid off. ...
Exelixis Announces Positive Results from Phase ... [Published Business Wire Health News - Sep 29 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, evaluating cobimetinib, a ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
Complete Response Letter from FDA, Positive Opi... [Published Financial Services - Jul 31 2014]
Biotech Companies Release Quarterly Financials ... [Published Financial Services - Jul 29 2014]
SEC Filings, Positive Trial Results, Technical ... [Published Financial Services - Jul 18 2014]
Technical Data on Health Care Sector Equities -... [Published Financial Services - Jul 10 2014]
Technical Data on Biotech Stocks -- Research on... [Published Financial Services - May 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.